<DOC>
	<DOC>NCT00776438</DOC>
	<brief_summary>To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations. Objectives: - To describe the immune response per age group and vaccine group after vaccination. - To describe the safety of the vaccines per age group and per vaccine group after vaccination.</brief_summary>
	<brief_title>Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 to 40 years (adults) or 60 to 85 years (elderly) Provision of a signed informed consent Able to attend all scheduled visits and comply with all trial procedures For a woman of childbearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until 4 weeks after vaccination Entitlement to national social security. Exclusion Criteria : For a woman of childbearing potential, known pregnancy or positive urine pregnancy test Breastfeeding woman Participation in another clinical trial investigating a vaccine, drug, medical device or a medical procedure in the 4 weeks preceding the trial vaccination Planned participation in another clinical trial during the present trial period Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months, or longterm systemic corticosteroids therapy Known systemic hypersensitivity to any of the vaccine components or history of a lifethreatening reaction to the trial vaccine or to a vaccine containing any of the same substances Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator Current alcohol abuse or drug addiction, which may interfere with the subject's ability to comply with trial procedures Receipt of blood or bloodderived products in the past 3 months, which might interfere with the assessment of immune response Receipt of any vaccine in the 4 weeks preceding the trial vaccination Planned receipt of any vaccine in the 4 weeks following the trial vaccination Known Human Immunodeficiency Virus, Hepatitis B or Hepatitis C seropositivity Previous vaccination against Influenza in the previous 6 months Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding the inclusion contraindicating IM vaccination Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent Febrile illness (oral temperature &gt;=37.5Â°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Myxovirus Infection</keyword>
	<keyword>Inactivated Split-virion influenza vaccine</keyword>
	<keyword>Adults</keyword>
	<keyword>Elderly</keyword>
</DOC>